Single-Dose Recombinant Activated Factor VII Therapy in Hemophilia Patients With Inhibitors

Seminars in Hematology

Volumn 45, Issue SUPPL. 1, 2008, Pages

  Kenet, Gili ^a   Martinowitz, Uri ^a  

^a The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA; HOME CARE; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR ACCESS;

BLOOD COAGULATION FACTOR INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 44649162404     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.03.011     Document Type: Article

References (25)

1. Santagostino E., Mancuso M.E., Rocino A., Mancuso G., Mazzucconi M.G., Tagliaferri A., et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 130 (2005) 422-427
2. White II G.C., Kempton C.L., Grimsley A., Nielsen B., and Roberts H.R. Cellular immune responses in hemophilia: Why do inhibitors develop in some, but not all hemophiliacs?. J Thromb Haemost 3 (2005) 1676-1681
3. Lusher J.M. Inhibitor antibodies to factor VIII and factor IX: Management. Semin Thromb Hemost 26 (2000) 179-188
4. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 26 (2000) 385-391
5. Key N.S., Aledort L.M., Beardsley D., Cooper H.A., Davignon G., Ewenstein B.M., et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80 (1998) 912-918
6. Ingerslev J., Thykjaer H., Kudsk Jensen O., and Fredberg U. Home treatment with recombinant activated factor VII: Results from one centre. Blood Coagul Fibrinolysis 9 suppl 1 (1998) S107-S110
7. Proulle V., Hugel B., Guillet B., Trichet C., Rafowicz A., Lambert T., et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost 91 (2004) 873-878
8. Carr Jr. M.E., Martin E.J., Kuhn J.G., and Seremetis S.V. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 89 (2003) 803-811
9. He S., Ekman G.J., and Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 3 (2005) 272-279
10. Erhardtsen E., Nony P., Dechavanne M., Ffrench P., Boissel J.P., and Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 9 (1998) 741-748
11. Sumner W.T., Monroe D.M., and Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 81 (1996) 533-543
12. Schulman S., d'Oiron R., Martinowitz U., Pasi J., Briquel M.E., Mauser-Bunschoten E., et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 9 suppl 1 (1998) S97-S101
13. Villar A., Aronis S., Morfini M., Santagostino E., Auerswald G., Thomsen H.F., et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 10 (2004) 352-359
14. Abshire T.C. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol 41 suppl 1 (2004) 3-7
15. Kenet G., Lubetsky A., Luboshitz J., and Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 1 (2003) 450-455
16. Cooper H.A., Jones C.P., Campion E., Roberts H.R., and Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 7 (2001) 517-522
17. Kenet G., Lubetsky A., Luboshitz J., Ravid B., Tamarin I., and Martinowitz U. High dose recombinant activated factor VII for treatment of patients with haemophilia and inhibitors. Haemophilia 10 (2004) 53-66 (abstr)
18. Parameswaran R., Shapiro A.D., Gill J.C., Kessler C.M., and HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11 (2005) 100-106
19. Kavakli K., Makris M., Zulfikar B., Erhardtsen E., Abrams Z.S., Kenet G., et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 95 (2006) 600-605
20. Santagostino E., Mancuso M.E., Rocino A., Mancuso G., Scaraggi F., and Mannucci P.M. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4 (2006) 367-371
21. Young G., Shafer F.E., Rojas P., and Seremetis S. Single 270 μg/kg-dose rFVIIa versus standard 90 μg/kg-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomised comparison. Haemophilia 14 (2008) 287-294
22. Abshire T., and Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2 (2004) 899-909
23. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2 (2004) 1700-1708
24. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., and Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
25. Konkle B.A., Ebbesen L.S., Erhardtsen E., Bianco R.P., Lissitchkov T., Rusen L., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5 (2007) 1904-1913